PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
402.37%
G&A change of 402.37% while AXSM maintains overhead. Bruce Berkowitz would investigate efficiency.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
547.73%
Operating expenses growth above 1.5x AXSM's 6.62%. Michael Burry would check for inefficiency.
547.73%
Total costs growth above 1.5x AXSM's 8.31%. Michael Burry would check for inefficiency.
3.95%
Interest expense growth less than half of AXSM's 24.56%. David Dodd would verify sustainability.
-96.03%
Both companies reducing D&A. Martin Whitman would check industry patterns.
-2633.53%
EBITDA decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-468.26%
Operating income decline while AXSM shows 35.57% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
6409.86%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
-429.59%
Pre-tax income decline while AXSM shows 17.64% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-75.15%
Tax expense reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine advantage.
-263.73%
Net income decline while AXSM shows 19.26% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-197.18%
EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
-197.18%
Diluted EPS decline while AXSM shows 20.49% growth. Joel Greenblatt would examine position.
22.83%
Share count reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.
22.83%
Diluted share reduction below 50% of AXSM's 1.17%. Michael Burry would check for concerns.